Features Partner Sites Information LinkXpress
Sign In
Demo Company

Future Chemotherapy Could Target Tumor Cell Social Interactions

By BiotechDaily International staff writers
Posted on 11 Oct 2012
Print article
Collections of cancer cells - tumors- display many characteristics of communal communication and social interaction that typify collections of bacterial cells, and an international team of theoretical biologists have suggested that development of new cancer treatments should be based on attacking tumors at the level of these social interactions.

Investigators at Rice University (Houston, TX, USA), Johns Hopkins University (Baltimore, MD, USA), and Tel Aviv University (Israel) suggested in a paper published in the September 2012 issue of the journal Trends in Microbiology that the communal behavior of bacteria represent a valuable model system for new perspectives and research directions in cancer chemotherapy. As an example they site the behavior of some types of cancer that revert to a dormant, unresponsive state when challenged by drug treatment. Absence of the drug stimulates a signaling process that reawakens the tumor.

“Cancer is a sophisticated enemy. There is growing evidence that cancer cells use advanced communications to work together to enslave normal cells, create metastases, resist drugs, and decoy the body’s immune system,” said first author Dr. Eshel Ben-Jacob, professor of physics at Tel Aviv University. “If we can break the communication code, we may be able to prevent the cells from going dormant or to reawaken them for a well-timed chemotherapeutic attack. This is just one example. Our extensive studies of the social lives of bacteria suggest a number of others, including sending signals that trigger the cancer cells to turn upon themselves and kill one another.”

Related Links:

Rice University
Johns Hopkins University
Tel Aviv University

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.